Bedrijfsoverzicht
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on the development of orally bioavailable small molecule therapeutic products aimed at treating cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The company functions within the Healthcare sector and specifically the Biotechnology industry, a classification that signifies its reliance on extensive research and development cycles before achieving commercial viability. As of the latest available data, the enterprise maintains a market capitalization of $6.85M and employs a workforce of 5 individuals, while reporting annual revenue of $405,000 over the trailing twelve-month period. These specific financial figures indicate that Can-Fite BioPharma Ltd. is a micro-cap entity with very limited revenue generation relative to its market valuation, suggesting a position typical of early-stage development firms where current sales do not yet reflect the potential future value of its pipeline assets.
Financiële gezondheid
The company reported a revenue of $405,000 for the trailing twelve months, yet recorded a net income of $-9,828,000 and an EBITDA of $-9,926,000, revealing a significant structural gap where operating expenses vastly exceed current income streams. This disparity between modest revenue and substantial losses is characteristic of biotechnology firms in the clinical stage, where high costs for research, development, and regulatory compliance dominate the cost structure before product launch. Free cash flow stands at $-4,985,750, which indicates a heavy consumption of cash reserves required to fund ongoing operations and development activities, thereby limiting immediate financial flexibility until future milestones are reached or external funding is secured. The balance sheet shows a cash position of $8.54M against total debt of $71,000, resulting in a debt-to-equity ratio of 1.27, which suggests a leveraged capital structure where liabilities are significant relative to shareholders' equity despite the low absolute debt amount. Liquidity is supported by a current ratio of 3.46, indicating that the company possesses 3.46 times more current assets than current liabilities, providing a robust buffer for meeting short-term obligations. However, the return on equity is -178.2% and the return on assets is -66.7%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the context of traditional profitability measures common in mature industries.
Waarderingsbeoordeling
Valuation metrics for Can-Fite BioPharma Ltd. present a complex picture due to the lack of positive earnings, with a trailing P/E ratio of N/A and a forward P/E of -4.00, implying that earnings are currently negative and the market is pricing in future profitability that has not yet materialized. The price-to-book ratio is 0.68, indicating that the market values the company at 68% of its book value, which often suggests a discount applied to biotechnology firms with intangible assets that are not fully captured on the balance sheet or where the risk profile warrants a lower valuation multiple. Alternative valuation metrics include a price-to-sales ratio of 16.92 and an EV/EBITDA of -0.41, suggesting that investors are willing to pay a significant premium relative to sales volume, which is typical for companies with promising clinical pipelines but no historical earnings to support traditional multiples. The stock has demonstrated high volatility, trading between a 52-week high of $36.40 and a 52-week low of $2.90, placing the current trading price at a level that reflects significant uncertainty and speculative sentiment relative to this wide range. Furthermore, the beta value of -0.10 is highly anomalous for equities, indicating a negative correlation with the broader market where the stock historically moves inversely to market trends, thereby offering a unique risk profile distinct from standard market exposure.
Growth & Income
Revenue growth year-over-year stands at -43.3%, while earnings growth is N/A due to the absence of profitable operations in the recent period, implying that the company is in a contractionary phase regarding top-line sales or is still in the pre-revenue stages of product development. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders but instead retains all resources to fund its clinical trials and operational expenses. The absence of a dividend payout confirms that the company's strategy focuses entirely on reinvesting any available capital into growth initiatives, such as advancing its lead drug candidate Piclidenoson through clinical phases, rather than providing current income to investors. Consequently, the overall growth and income profile is defined by negative revenue trends and zero dividend distribution, characteristic of a clinical-stage biopharmaceutical company that must rely on cash reserves and potential future capital raises to sustain operations and achieve commercial breakthroughs.